COST-EFFECTIVENESS OF DIAGNOSING AXIAL SPONDYLOARTHRITIS IN THE NETHERLANDS

被引：0
|
作者：
Webers, C. [1 ,2 ]
Grimm, S. [2 ,3 ]
Van Tubergen, A. [1 ,2 ]
Van Gaalen, F. A. [4 ]
Van der Heijde, D. [4 ]
Joore, M. [2 ,3 ]
Boonen, A. [1 ,2 ]
机构：
[1] MUMC, Rheumatol, Maastricht, Netherlands
[2] Maastricht Univ, CAPHRI, Maastricht, Netherlands
[3] MUMC, Clin Epidemiol & Med Technol Assessment, Maastricht, Netherlands
[4] LUMC, Rheumatol, Leiden, Netherlands
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2020年 / 79卷
关键词：
D O I：
10.1136/annrheumdis-2020-eular.1065
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THU0549
引用
收藏
页码：510 / 511
页数：2
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF CERTOLIZUMAB PEGOL FOR THE TREATMENT OF AXIAL SPONDYLOARTHRITIS IN TURKEY
    Gaglayan, B.
    Firidin, A.
    Yildirim, N.
    Tatar, M.
    Essiz, M.
    VALUE IN HEALTH, 2015, 18 (07) : A645 - A645
  • [2] COST-EFFECTIVENESS ANALYSIS OF A CAFASPA REFERRAL MODEL FOR AXIAL SPONDYLOARTHRITIS
    Abdelkadir, M. J.
    Kuijper, M.
    Appels, C.
    Spoorenberg, A.
    Hazes, J.
    Van Hoeven, L.
    Barreto, D. Lopes
    Weel, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 175 - 176
  • [3] COST-EFFECTIVENESS ANALYSIS OF BIMEKIZUMAB IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS (AXSPA) IN GREECE
    Koulentaki, M.
    Ravanidis, S.
    Daoussis, D.
    Dimitroulas, T.
    Papagoras, C.
    Sfikakis, P.
    Kountouris, V
    Feretos, M.
    Kourlaba, G.
    Lyris, N.
    Willems, D.
    VALUE IN HEALTH, 2024, 27 (12) : S109 - S109
  • [4] The cost-effectiveness of zemplar in the Netherlands
    Nuijten, MJ
    Siegert, C
    VALUE IN HEALTH, 2006, 9 (03) : A7 - A8
  • [5] Cost-effectiveness Analysis of Golimumab in the Treatment of Non-Radiographic Axial Spondyloarthritis in Scotland
    Rebekah H. Borse
    Sumesh Kachroo
    Chloe Brown
    Eilish McCann
    Ralph P. Insinga
    Rheumatology and Therapy, 2018, 5 : 57 - 73
  • [6] Cost-effectiveness Analysis of Golimumab in the Treatment of Non-Radiographic Axial Spondyloarthritis in Scotland
    Borse, Rebekah H.
    Kachroo, Sumesh
    Brown, Chloe
    McCann, Eilish
    Insinga, Ralph P.
    RHEUMATOLOGY AND THERAPY, 2018, 5 (01) : 57 - 73
  • [7] A COST-EFFECTIVENESS MODEL OF ADALIMUMAB (ADA) IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS IN SPAIN
    Ji, X.
    Joshi, A.
    Vidal Perez-Campoamor, S.
    Sanchez Hernandez, R.
    Botteman, M.
    Bao, Y.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 122 - 123
  • [8] Cost-effectiveness model of Palivizumab in The Netherlands
    Nuijten, MJ
    Lebmeier, M
    Daalderop, P
    Wittenberg, W
    VALUE IN HEALTH, 2005, 8 (06) : A52 - A52
  • [9] Cost-effectiveness of statin therapy in The Netherlands
    Goes, ES
    VanHout, BA
    AMERICAN JOURNAL OF MANAGED CARE, 1997, 3 (10): : LC3 - LC3
  • [10] Cost-effectiveness of rotavirus vaccination in the Netherlands
    Welte, R
    Jager, JC
    Van Duynhoven, Y
    De Wit, M
    CLINICAL INFECTIOUS DISEASES, 2001, 33 (07) : 1228 - 1228
12345